FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
--

OMB APPROVAL											
OMB Number: 3235-0											
Estimated average burden											
hours per response:	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*  Nameurth Manlane					2. Issuer Name and Ticker or Trading Symbol Monte Rosa Therapeutics, Inc. [ GLUE ]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
Warmuth Markus				-				_1			- 1		X	Director			10% Ow	ner
(Last) (First) (Middle)					Date of Earliest Transaction (Month/Day/Year)						X	Officer ( below)	give title		Other (s below)	pecify		
MONTE ROSA THERAPEUTICS, INC.					01/03/2023							President & CEO						
645 SUMMER STREET, SUITE 102				L														
(Stroot)					4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street) BOSTO	N M	ÍΑ	02210										X	Form file	ed by One	Report	ting Person	
														Form filed by More than One Reporting Person				
(City)	(S	tate)	(Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date				2. Transact Date Month/Day	Execution Date,		Transaction Disposed Code (Instr.		ities Acquired (A) o d Of (D) (Instr. 3, 4			5. Amoun Securities Beneficial Owned Fo Reported	Forn Sollowing (1) (Ir		Direct Indirect Itr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	unt (A) or (D)		Price	Transactio (Instr. 3 a	tion(s)			msu. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Code	action (Instr.	Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)		Date Exercisable		kpiration ate	Title	or Nur	ount mber Shares		(Instr. 4)	214(3)		
Stock Option (Right to Buy)	\$7.78	01/03/2023		A		472,000		(1)	01	1/02/2033	Common Stock	47	2,000	\$0.00	472,00	0	D	

## **Explanation of Responses:**

1. 25% of this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

## Remarks:

/s/ Ajim Tamboli, Attorney-in-

**Fact** 

01/04/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.